Indaptus Therapeutics Inc
NASDAQ:INDP
Intrinsic Value
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one INDP stock under the Base Case scenario is 1.56 USD. Compared to the current market price of 2.18 USD, Indaptus Therapeutics Inc is Overvalued by 28%.
Valuation Backtest
Indaptus Therapeutics Inc
Run backtest to discover the historical profit from buying and selling INDP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Indaptus Therapeutics Inc
Current Assets | 14m |
Cash & Short-Term Investments | 13.4m |
Other Current Assets | 633.2k |
Non-Current Assets | 928.7k |
PP&E | 173.9k |
Other Non-Current Assets | 754.7k |
Current Liabilities | 2.8m |
Accounts Payable | 806k |
Accrued Liabilities | 2m |
Non-Current Liabilities | 73.4k |
Other Non-Current Liabilities | 73.4k |
Earnings Waterfall
Indaptus Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-16.4m
USD
|
Operating Income
|
-16.4m
USD
|
Other Expenses
|
955k
USD
|
Net Income
|
-15.4m
USD
|
Free Cash Flow Analysis
Indaptus Therapeutics Inc
INDP Profitability Score
Profitability Due Diligence
Indaptus Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Indaptus Therapeutics Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
INDP Solvency Score
Solvency Due Diligence
Indaptus Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Indaptus Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INDP Price Targets Summary
Indaptus Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for INDP is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 12.6 USD.
Ownership
INDP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
INDP Price
Indaptus Therapeutics Inc
Average Annual Return | -71.9% |
Standard Deviation of Annual Returns | 15.2% |
Max Drawdown | -100% |
Market Capitalization | 18.3m USD |
Shares Outstanding | 8 538 880 |
Percentage of Shares Shorted | 1.67% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. The company designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, is in pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs) in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.
Contact
IPO
Employees
Officers
The intrinsic value of one INDP stock under the Base Case scenario is 1.56 USD.
Compared to the current market price of 2.18 USD, Indaptus Therapeutics Inc is Overvalued by 28%.